Engineered dual RNAi prodrug for combined suppression of survival and cell cycle pathways in triple negative breast cancer treatment.

Authors

Swetha Vaishnavi, Soumyadeep Poddar, Srinivasa Reddy Bonam, Satheesh Ellipilli

Published in

Chemical communications (Cambridge, England). Oct 16, 2026. Epub Oct 16, 2026.

Abstract

Triple-negative breast cancer (TNBC) is highly aggressive, with limited effective therapies and poor clinical outcomes. Here, we developed a dual RNAi prodrug with enhanced in vitro therapeutic efficacy by simultaneously silencing two overexpressed BCL2 and CDK1 genes associated with tumor survival and cell cycle progression pathways, respectively, in TNBC cells. Compared with conventional dual siRNA treatment, the dual RNAi prodrug exhibited efficient gene silencing and improved anticancer activity through coordinated suppression of survival and cell cycle pathways.

PMID:
42885730
Bibliographic data and abstract were imported from PubMed on 16 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.